hotspot -WSS

hotspot

author：knowledge 2025-10-02 00:42:45 - browse：6659

Grail spent more than $1 million last quarter lobbying Congress, underscoring the urgency of the company’s bid to secure Medicare coverage for its pricey blood-based cancer screening test that has been on the market for over a year but is not widely used.

A recently posted lobbying report indicates that, during the fourth quarter of last year, the biotech spent $1.07 million on “issues related to oncology and multi-cancer early detection,” including House and Senate bills that would allow Medicare to cover multi-cancer screening tests. That figure has been rising; during the fourth quarter of 2021, the company spent $470,000 on lobbying. That’s far more than cancer and genetic testing biotechs such as Guardant Health, Myriad Genetics, and Tempus, which spent anywhere from $90,000 to nearly $300,000 on lobbying last quarter.

The growing investment in lobbying elected officials comes at a time when Grail is looking to make its test, Galleri, available to a broader swath of the population. The test, launched in 2021, can detect early signs of more than 50 cancers among people who don’t have symptoms. That’s because cancer cells release bits of DNA into the bloodstream, and Galleri spots telltale modifications to this DNA.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： The creative science of coining drug names

WSS

Elevance, SCAN deals highlight health insurer acquisition scrutiny

As health system earnings go up, health insurance stocks go down

Flagship Pioneering startup Sonata Therapeutics lays off 21

Opioid cravings were reduced by anti

PBM executives asked to testify by House panel

Brain technologies pose threats that are all too real, experts warn

knowledge

hotspot

explore

Anesthesiologist group: stop taking Ozempic before surgery

Measles policy set amid Florida outbreak alarms vaccine proponents

Supreme Court strikes down use of affirmative action

Medicare Advantage enrollment grows 7.1% to 33.4 million people

United colonoscopy coverage change 'may cost lives,' doctors say

As health system earnings go up, health insurance stocks go down

Heart attack and stroke risk calculators need revising

A new drug could help frostbite victims avoid its ravages

Sports medicine is finally prioritizing gender equality

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

knowledge

Readout Newsletter: PTC, Dyne, Rapport, Cytokinetics news

How a small hospital in rural Puerto Rico survived Hurricane Maria

Medicare Advantage enrollment hits roughly 33.4 million

New study raises questions about niacin and heart health

Ukraine seeks to reclaim its role as a hub for clinical trials

Elevance, SCAN deals highlight health insurer acquisition scrutiny

leisure time

explore

hotspot

leisure time